Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON28091
NL-OMON28091RecruitingNot Applicable

Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma

Erasmus Medical Center, Rotterdam0 sites20 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
20
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

de Boer NL, van Kooten JP, Burger JWA, Verhoef C, Aerts J, Madsen EVE. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial. BMJ Open. 2019;9(5):e026779. van Kooten JP, de Boer NL, Burger JWA, Verhoef C, Aerts J, Madsen EVE. Adjuvante Dendritische Cel Immunotherapie na Cytoreductieve Chirurgie en Hypertherme Intraperitoneale Chemotherapie voor patiënten met Maligne Peritoneaal Mesothelioom. De MESOPEC studie. Nederlands Tijdschrift voor Oncologie. Jaargang 16, Nummer 2, Maart 2019.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •In order to be eligible to participate in this study, a subject must meet all of the following criteria, before undergoing CRS-HIPEC:
  • •Patients with a histologically or cytologically confirmed diagnosis of malignant peritoneal mesothelioma

Exclusion Criteria

  • •A potential participant who meets any of the following criteria will be excluded from participation in the study:
  • •Extra-abdominal disease/ metastatic disease

Investigators

Sponsor
Erasmus Medical Center, Rotterdam

Similar Trials

Completed
Phase 2
Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesotheliomaasbestos cancerperitoneal mesenthelioma10027412
NL-OMON48572Erasmus MC, Universitair Medisch Centrum Rotterdam18
Active, not recruiting
Phase 1
Personalized dendritic cell-based immune therapy for improving treatment of children with brain (stem) tumorsChildhood high-grade glioma and diffuse intrinsic pontine gliomaMedDRA version: 20.0Level: LLTClassification code 10046859Term: VaccinationSystem Organ Class: 100000004865MedDRA version: 20.0Level: PTClassification code 10006143Term: Brain stem gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10080666Term: Diffuse intrinsic pontine gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2020-004125-23-BEAntwerp University Hospital10
Active, not recruiting
Phase 1
Dendritic cell-based immunotherapy for advanced solid tumours of children and young adultsChildren and young adults with advanced solid tumours: relapsed or metastatic sarcomas or central nervous system tumours.
EUCTR2013-003632-71-ESClínica Universidad de Navarra/Universidad de Navarra10
Not yet recruiting
Phase 1
Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After ATI in HIV Infected IndividualsHIV Vaccine
NCT05786937University of Sao Paulo General Hospital30
Not yet recruiting
Not Applicable
Dendritic cell-based immunotherapy combined with low-dose cyclophosphamide in patients with malignant pleural mesotheliomamesothelioma10035597
NL-OMON32554Erasmus MC, Universitair Medisch Centrum Rotterdam10